Skip to content

Prices inUSD

Cart0

BPC-157 vs TB-500: Comparing Two Research Peptides by Structure

BPC-157 vs TB-500: Comparing Two Research Peptides by Structure

BPC-157 and TB-500 get searched as a pair more than almost any other research peptides, yet they share almost nothing chemically. On one side is a synthetic chain of fifteen amino acids; on the other, a seven-residue piece trimmed from thymosin beta-4, a 43-residue protein present in nearly every cell type.

So where does BPC-157 vs TB-500 actually differ, molecule to molecule? This guide walks through where each molecule comes from, lines up their structures, maps the signalling and actin assays behind each one, explains why catalogues pair them, and shows which COA fields separate them, finishing with their dated US status.

Quick answer: BPC-157 vs TB-500. BPC-157 (PL 14736) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV and a mass of 1419.5 g/mol. TB-500 is usually the acetylated heptapeptide Ac-LKKTETQ, residues 17-23 of thymosin beta-4 (889.0 g/mol). In cell work, BPC-157 shows up in VEGFR2, nitric-oxide and FAK signalling readouts, while TB-500 shows up in actin and cell-migration readouts.

✔ Unrelated sequences with no shared motif

✔ BPC-157 is about 1.6 times heavier

✔ Both are research reagents, confirmed by LC-MS mass

BPC-157 vs TB-500 at a Glance

Origin, chain length, mass, and research target all separate these two. BPC-157 is a fifteen-residue sequence made entirely by synthesis; TB-500 is an acetylated seven-residue piece of thymosin beta-4. Labs use BPC-157 to probe kinase signalling in cultured cells and TB-500 to probe actin in cell-free and cell-based systems.

BPC-157TB-500
Other namesPL 14736, pentadecapeptide BPC 157Thymosin beta-4 fragment, Tβ4 (17-23)
TypeSynthetic linear pentadecapeptideAcetylated heptapeptide; fragment of a 43-residue protein
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-ValAc-Leu-Lys-Lys-Thr-Glu-Thr-Gln
Length15 residues7 residues
FormulaC62H98N16O22 (free base)C38H68N10O14
Molecular weight1419.5 g/mol889.0 g/mol
CAS137525-51-0885340-08-9 (PubChem synonym)
OriginTaken from a larger parent protein; made by solid-phase synthesisActin-binding motif of thymosin beta-4; synthesised
Targets studied in vitroVEGFR2, eNOS / NO, FAK-paxillin, ERK1/2G-actin binding, actin polymerization
Typical assaysWestern blot, Griess, tube formation, scratch/transwell migrationPyrene-actin polymerization, DNase I inhibition, co-sedimentation, migration
Common formsFree base or acetateFree base or acetate
CellugenixBPC-157 10 mgTB-500 5 mg

Read the table as two separate identity cards. Nothing on the BPC-157 side predicts anything on the TB-500 side, which is the first thing to grasp about the difference between BPC-157 and TB-500: they’re unrelated reagents that happen to share a shelf.

What Is BPC-157?

BPC-157, catalogued under the code PL 14736, is a fifteen-amino-acid synthetic chain, GEPPPGKPADDAGLV, weighing 1419.5 g/mol in free-base form. Its sequence was taken from a larger parent protein. Cell-culture studies use it to probe VEGFR2, nitric-oxide, and FAK-paxillin signalling.

Every batch is made by solid-phase synthesis, so the research material is a defined pentadecapeptide with a fixed sequence and a PubChem entry (CID 9941957, CAS 137525-51-0). The BPC-157 research overview covers the published cell-level work in more depth.

A Proline-Rich, Acidic Chain

Four of its fifteen residues are proline, three of them in an unbroken PPP run at positions 3 to 5. Two aspartates and one glutamate outnumber its lone lysine, leaving the chain negatively charged near pH 7. Both features show up in the lab. Proline runs resist fragmentation in some MS methods, and the Asp-Asp pair at positions 10-11 is a known site for aspartate isomerisation, which produces an impurity with exactly the same mass as the parent. Truncated chains, missing a residue from either end, are the other impurity to look for.

Free Base vs Acetate

Vials of BPC-157 may hold the free base or come as an acetate salt. The chain is identical either way; the acetate counter-ions simply add weight, which changes the formula weight a label should quote. A COA should state which form it describes, otherwise the measured content can’t be compared with the label.

What Is TB-500?

TB-500 is a made-to-order copy of the actin-binding stretch of thymosin beta-4 (Tβ4), the 43-residue protein abundant in nearly all cells. In most catalogues, the name means Ac-LKKTETQ, Tβ4 residues 17-23 with an acetyl cap, a heptapeptide studied in cell-free actin work and cell-migration assays.

PubChem lists the heptapeptide as CID 62707662, formula C38H68N10O14 at 889.0 g/mol, with CAS 885340-08-9 among its synonyms. The acetyl group on the N-terminal leucine is part of the identity, and so is the free acid at the C-terminal glutamine.

Why this particular stretch? The LKKTET sequence is the recognised actin-binding motif of the beta-thymosin family, and versions of it turn up in other actin-binding proteins too. Cutting the protein down to that motif plus one flanking glutamine gives a short, cheap-to-make peptide with one clear job in the literature: probing the actin contact without the other 36 residues of the parent protein. 

That convenience comes with a question every lab should ask, covered in the assay section below: how much of the full protein’s behaviour does the fragment keep? The TB-500 research overview goes further into the fragment literature.

Is TB-500 the Same as Thymosin Beta-4?

No. The parent protein runs to 43 residues after its starting methionine is removed, opens with an acetylated serine, and weighs about 4,963 g/mol (UniProt P62328; PubChem CID 45382195). TB-500 is one seven-residue stretch of it. The name isn’t standardised, though, and some products sold as “TB-500” contain longer fragments or the full protein. A measured LC-MS mass is what decides it for any given lot.

TB-500 (Ac-LKKTETQ)Thymosin beta-4
Residues743
Expected mass889.0 g/mol~4,963 g/mol
What the COA should showLC-MS mass near 889 DaLC-MS mass near 4,963 Da

Not Thymosin Alpha-1

Thymosin alpha-1 is an unrelated 28-residue peptide. It shares the “thymosin” name for historical reasons; the sequences are unrelated. The history behind that shared name is set out in our thymosin alpha-1 vs thymosin beta-4 comparison.

How Do Their Structures Compare?

BPC-157 is about twice as long as TB-500 and roughly 1.6 times heavier. The two sequences share no dipeptide motif. BPC-157 is proline-rich and acidic overall; TB-500 carries two adjacent lysines and an acetylated N-terminus. Their LC-MS masses fall more than 500 Da apart, so the two are easy to distinguish analytically.

PropertyBPC-157TB-500
Residues157
Molecular weight (g/mol)1419.5889.0
N-terminusFree amine (Gly)Acetylated (Ac-Leu)
Charged residuesGlu, Lys, Asp, AspLys, Lys, Glu
Net charge, pH 7 (approx.)−2~0
Proline content4 of 150 of 7
Shared motifNoneNone
Solubility noteSoluble in water/DMSO for assay preparationSoluble in water/DMSO for assay preparation

Those differences show up the moment either peptide reaches an instrument. On reversed-phase HPLC, the two elute at different retention times because their size and hydrophobicity differ. In electrospray MS, BPC-157 often appears as both a singly and a doubly charged ion, while the smaller TB-500 gives a strong singly charged signal near 889.5. The acetyl group is the detail most often missed: an unacetylated LKKTETQ weighs 42 Da less, so a TB-500 COA has to report a mass that includes it.

Charge affects handling too. With BPC-157 acidic overall and TB-500 close to neutral, the two respond differently to buffer pH and to ion-exchange clean-up. Anyone comparing them in one assay plate should prepare each from its own documented stock and record the buffer used.

BPC-157 15-residue sequence GEPPPGKPADDAGLV compared on one scale with the 7-residue TB-500 sequence Ac-LKKTETQ, with acidic, basic, proline and acetyl residues colour-coded and calculated pI values of 3.7 and 7.1

BPC-157 15-residue sequence GEPPPGKPADDAGLV compared on one scale with the 7-residue TB-500 sequence Ac-LKKTETQ, with acidic, basic, proline and acetyl residues colour-coded and calculated pI values of 3.7 and 7.1

What Are They Studied Against in the Lab?

In endothelial and fibroblast cultures, BPC-157 acts as a probe for kinase signalling, read out through VEGFR2 and eNOS phosphorylation, nitric-oxide output, and FAK-paxillin activity. TB-500 belongs to actin biochemistry: monomer binding and polymerization in purified-protein systems, with cytoskeleton staining and migration assays in cultured cells.

On the BPC-157 side, the clearest example is a 2017 study in J Mol Med (Hsieh et al., PMID 27847966). In cultured human vascular endothelial cells, it reported raised VEGFR2 expression and internalisation, plus time-dependent activation of the VEGFR2-Akt-eNOS pathway. Fibroblast work follows a different route, centred on the focal-adhesion machinery: in primary rat fibroblast cultures, Chang et al. (2011, PMID 21030672) measured transwell migration, cell spreading, phalloidin-stained F-actin and concentration-dependent phosphorylation of FAK and paxillin by Western blot.

For TB-500, the foundation is biochemical. In a cell-free system, Safer et al. (1991, PMID 1999398) showed that full-length thymosin beta-4 forms a 1:1 complex with G-actin and blocks salt-induced polymerization. The heptapeptide itself was tested by Philp et al. (2003, PMID 14500546) in HUVEC migration and adhesion assays alongside the full protein.

Each readout answers a narrow question. The pyrene-actin assay uses actin labelled with a fluorescent pyrene group that brightens as monomers join filaments, so a peptide capable of actin sequestration slows the rise in signal. The DNase I inhibition assay relies on the fact that G-actin inhibits DNase I while F-actin doesn’t, so a peptide that holds actin in its monomeric form keeps the enzyme inhibited. 

On the BPC-157 side, the Griess assay measures nitrite, a stable breakdown product of nitric oxide, in culture supernatant, and phospho-specific Western blots track VEGFR2, eNOS, FAK, paxillin and ERK1/2.

BPC-157TB-500
Model systemsHUVEC / endothelial cells, fibroblast culturesPurified actin (cell-free), cultured cell lines
Main readoutsp-VEGFR2, p-eNOS, NO (Griess), p-FAK / paxillin, ERK1/2G-actin binding, pyrene-actin polymerization rate, DNase I inhibition, phalloidin-stained F-actin
Receptor questionNone confirmed; read out via downstream kinasesBinds actin directly, with no receptor involved
Shared assaysScratch / transwell migration; phalloidin F-actin stainingScratch / transwell migration; phalloidin F-actin staining
Study type to labelIn vitro (cell culture)Cell-free and in vitro

Fragment vs Full Protein in the Literature

A large share of actin papers test the whole 43-residue protein, and findings from those papers can’t simply be transferred to the seven-residue fragment. A DNase I inhibition study by Hannappel and Wartenberg (1993, PMID 8471179) tested enzyme-generated Tβ4 fragments in a cell-free assay and found that some longer pieces lost the full protein’s G-actin sequestering activity. Every paper should say which molecule it used, and the same caution applies to BPC-157 studies.

A kinase-signalling probe vs an actin-binding fragment: that one line is the simplest way to keep their lab roles apart.

Map of the 43-residue thymosin beta-4 sequence with the TB-500 stretch, residues 17 to 23, highlighted, and bars for full-length thymosin beta-4 and the fragments tested in cell-free actin assays and endothelial-cell migration assays

Map of the 43-residue thymosin beta-4 sequence with the TB-500 stretch, residues 17 to 23, highlighted, and bars for full-length thymosin beta-4 and the fragments tested in cell-free actin assays and endothelial-cell migration assays

Why Are BPC-157 and TB-500 Often Supplied Together?

Mainly because suppliers list them side by side, and some sell them as a set or a premixed vial. Structurally, they’re unrelated, and published studies examine them separately in different assay systems. At Cellugenix, each one is available as its own vial with its own batch COA.

That shared shelf space creates one practical risk: two white lyophilised powders that look identical. When a lab works with BPC-157 and TB-500 in the same week, every vial still needs its own identity check, because a shared listing changes nothing about what each certificate has to show. A simple bench routine prevents mix-ups: store the two in separately labelled boxes, record each report number in the notebook before first use, and confirm each vial’s mass by LC-MS on arrival when the certificate stops at HPLC.

Comparing TB-500 vs BPC-157 is easy on paper and surprisingly easy to get wrong on a crowded bench. The single-compound pages carry the current reports: BPC-157 10 mg and TB-500 5 mg.

How Do They Compare With GHK-Cu and KPV?

GHK-Cu and KPV are the two other peptides most often listed next to BPC-157 and TB-500. Both are far smaller: GHK-Cu is the copper complex of the tripeptide Gly-His-Lys, and KPV is the three-residue C-terminal fragment of alpha-MSH, Lys-Pro-Val.

BPC-157TB-500GHK-CuKPV
Residues1573 (+ Cu²⁺)3
SequenceGEPPPGKPADDAGLVAc-LKKTETQGly-His-Lys · CuLys-Pro-Val
Approx. mass (g/mol)1419.5889.0~403342.4
Main assay focusVEGFR2 / NO / FAKG-actin bindingCopper-binding assaysNF-κB reporter, PepT1 uptake

Put all four in a row and BPC-157 is the outlier, at roughly four times the mass of either tripeptide. Each has its own guide: BPC-157 vs KPV, the GHK-Cu copper peptide guide and the KPV research overview. The KPV vs TB-500 comparison sets KPV and TB-500 side by side.

What’s Their US Regulatory Status?

Neither BPC-157 nor TB-500 is an FDA-approved drug. What labs buy is reagent-grade material carrying a Research Use Only label. Both have appeared in FDA’s review of bulk substances nominated for compounding, a process aimed at licensed compounding pharmacies.

DateEventSource
April 22, 2026 (page date)BPC-157, TB-500 (“thymosin beta-4, fragment (LKKTETQ)”) and KPV appear among category 2 nominations withdrawn by their nominatorsFDA bulk drug substances page
July 23, 2026FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 and TB-500 (free base and acetate) for the 503A bulks listFDA Law Blog, July 24, 2026
After the voteNon-binding; FDA decides through notice-and-comment rulemakingFDA Law Blog, July 24, 2026
October 14, 2026HHS and FDA sent an interim compounding access policy for certain peptides to OMB; not issued as of October 16Holland & Knight, October 16, 2026

A withdrawn nomination leaves a substance outside FDA’s interim compounding categories altogether; it has no bearing on how research reagents are labelled or sold. The July vote moved the question forward for pharmacies, and the October policy still awaited White House review when this guide was updated.

Advisory votes are non-binding and apply to compounding pharmacies; research reagents follow Research Use Only labelling rules. Our explainer on what research peptides are covers the RUO category in full. Treat this section as background reading; it isn’t legal advice.

How to Tell BPC-157 and TB-500 Apart on a COA

A usable COA for either peptide names the full sequence, shows an HPLC chromatogram behind its purity figure, and reports an LC-MS mass matching that sequence. BPC-157 shows [M+H]+ near 1419.7; Ac-LKKTETQ near 889.5. A TB-500 mass near 4,960 means full-length thymosin beta-4, a different molecule.

CheckBPC-157TB-500
Expected [M+H]+ (monoisotopic)1419.7889.5 for Ac-LKKTETQ; ~4,961 if full-length Tβ4
Must stateFree base or acetateAcetylated N-terminus; fragment or full length
Impurities to watchTruncations; Asp isomerisation (same mass)Des-acetyl form (−42 Da); truncations
Current reportLK-BPC-10-052226 (Testides, issued May 27, 2026)CPT-TB500-72578C (Canada Peptide Testing, issued October 2, 2026)
PurityPurity by HPLC, see the batch resultPurity by HPLC, see the batch result
MS on current reportNot includedNot included

Both current Cellugenix reports are HPLC-UV reports. For BPC-157, report LK-BPC-10-052226 gives purity by HPLC, see the batch result: 10.69 mg measured against 10.00 mg expected. TB-500 lot CGX-2025 was run on September 28, 2026 under report CPT-TB500-72578C: purity by HPLC, see the batch result, and 4.98 mg found versus 5.00 mg on the label, a 99.6% fill. Neither report includes an LC-MS mass, so a lab that needs identity confirmation orders MS separately. Both certificates can be opened from the COA library (BPC-157 10 mg, TB-500 5 mg). For a field-by-field walkthrough, see reading a COA and HPLC vs mass spectrometry.

When a certificate stops at HPLC, a quick LC-MS run on receipt closes most of the identity questions. Look for the expected [M+H]+ ion, then scan 42 Da below it on a TB-500 sample for the des-acetyl form. Aspartate isomerisation in BPC-157 is harder, because the isomer weighs exactly the same; it shows up as a shoulder or a second peak on a well-resolved HPLC trace, which is why the chromatogram deserves a read alongside the purity figure.

Storing the Sealed Vial

Hold each vial sealed, cold, dry and away from light, following the conditions printed on its label and certificate, and note its report number in every protocol that draws on it. Lot-tracking habits for freeze-dried material are set out in our storage guide.

Frequently Asked Questions

What’s the difference between BPC-157 and TB-500?

Fifteen residues against seven, and 1419.5 against 889.0 g/mol. BPC-157 is probed with VEGFR2, nitric-oxide and FAK readouts; TB-500, an acetylated thymosin beta-4 fragment, with actin and migration readouts. The two sequences have no motif in common.

Is BPC or TB500 better?

Neither is “better”. They’re unrelated molecules studied against different targets: BPC-157 against kinase signalling pathways, TB-500 against actin. A lab picks the one that matches what its assay measures, then confirms identity on the batch COA.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is usually residues 17-23 of thymosin beta-4, acetylated, at about 889 g/mol. The parent protein has 43 residues and weighs about 4,963 g/mol. The LC-MS mass on the COA shows which one a vial contains.

Are BPC-157 and TB-500 sold together?

Some suppliers offer them as a set or a premixed vial. Cellugenix supplies each as its own vial with its own batch COA, and published studies examine the two peptides separately, in different assay systems.

Do BPC-157 and TB-500 share any sequence?

No. BPC-157 (GEPPPGKPADDAGLV) and TB-500 (Ac-LKKTETQ) share no dipeptide motif. They also differ at the N-terminus: BPC-157 starts with a free glycine amine, while TB-500 starts with an acetylated leucine.

Is the “Wolverine” blend BPC-157 and TB-500?

That name is a market nickname for a product containing BPC-157 and TB-500. This guide uses composition names only. For any product sold under a nickname, check that the COA identifies each component by name and mass.

Are BPC-157 and TB-500 FDA-approved?

No. Both are sold as research reagents. On FDA’s compounding list page (dated April 22, 2026) both appear as withdrawn nominations. A July 23, 2026 advisory vote favoured adding them to the 503A list, a recommendation FDA isn’t bound to follow.

The Bottom Line

BPC-157 and TB-500 share search results far more than chemistry. One is a fifteen-residue synthetic chain used as a kinase-signalling probe; the other is a seven-residue thymosin beta-4 fragment used in actin work. Match the peptide to the target the assay reads, and check its identity against an LC-MS mass on a report that verifies online. Current batches: BPC-157 10 mg and TB-500 5 mg.

For laboratory research use only. Not for human or animal use. Terms

Sources

For laboratory research use only. Not for human or animal use.

0